Padmanabh Bhatt the Sr. VP of IP – CSO of Supernus Pharmaceuticals, Inc. (SUPN) Unloaded 7,868 Shares of the Company; Menta Capital Raised Its Builders Firstsource (BLDR) Stake

May 17, 2018 - By Winifred Garcia

Builders FirstSource, Inc. (NASDAQ:BLDR) Logo

Menta Capital Llc increased Builders Firstsource Inc (BLDR) stake by 207.1% reported in 2017Q4 SEC filing. Menta Capital Llc acquired 122,090 shares as Builders Firstsource Inc (BLDR)’s stock declined 7.53%. The Menta Capital Llc holds 181,041 shares with $3.95M value, up from 58,951 last quarter. Builders Firstsource Inc now has $2.17 billion valuation. The stock increased 4.23% or $0.77 during the last trading session, reaching $18.97. About 1.49M shares traded or 36.28% up from the average. Builders FirstSource, Inc. (NASDAQ:BLDR) has risen 35.87% since May 17, 2017 and is uptrending. It has outperformed by 24.32% the S&P500.

As published in a legal document that was filled with the U.S. Security and Exchange Commission on 16-05-2018, Padmanabh Bhatt an insider in Supernus Pharmaceuticals Inc and currently Sr. VP of IP – CSO, made a sale of shares worth $455,759 US Dollars in the public firm. He sold 7,868 shares, at average $57.9 per share. In the last month, he also unloaded 67,132 shares worth about $3,565,713 USD. Padmanabh Bhatt currently possess 7,500 shares which are around 0.01% of the Maryland-based company’s total market cap.

Another recent and important Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) news was published by Seekingalpha.com which published an article titled: “Supernus Pharmaceuticals’ (SUPN) CEO, Jack Khattar on Q1 2018 Results – Earnings Call Transcript” on May 09, 2018.

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. The company has market cap of $3.02 billion. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. It has a 42.5 P/E ratio. The company??s product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder ; and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD.

Among 11 analysts covering Supernus Pharmaceuticals (NASDAQ:SUPN), 8 have Buy rating, 0 Sell and 3 Hold. Therefore 73% are positive. Supernus Pharmaceuticals has $6800 highest and $27 lowest target. $49.55’s average target is -15.08% below currents $58.35 stock price. Supernus Pharmaceuticals had 39 analyst reports since August 26, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Tuesday, September 19 by Stifel Nicolaus. Cantor Fitzgerald maintained the shares of SUPN in report on Wednesday, September 27 with “Buy” rating. Zacks downgraded the stock to “Hold” rating in Wednesday, August 26 report. The firm has “Buy” rating given on Monday, July 17 by Stifel Nicolaus. Piper Jaffray maintained Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) rating on Friday, October 27. Piper Jaffray has “Hold” rating and $41.0 target. The rating was initiated by Northland Capital on Wednesday, October 28 with “Outperform”. The stock has “Buy” rating by Jefferies on Thursday, August 4. On Monday, October 23 the stock rating was maintained by Cowen & Co with “Buy”. As per Friday, October 20, the company rating was maintained by Stifel Nicolaus. The stock of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) earned “Outperform” rating by Northland Capital on Thursday, November 5.

The stock increased 0.43% or $0.25 during the last trading session, reaching $58.35. About 728,589 shares traded or 1.61% up from the average. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has risen 46.59% since May 17, 2017 and is uptrending. It has outperformed by 35.04% the S&P500.

Since January 2, 2018, it had 0 buys, and 10 selling transactions for $15.40 million activity. Vaughn Victor also sold $1.12 million worth of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) on Wednesday, January 17. Another trade for 20,000 shares valued at $899,500 was sold by Bhatt Padmanabh P. 50,000 shares were sold by PATRICK GREGORY S, worth $2.18 million on Thursday, January 11.

Investors sentiment increased to 1.1 in Q4 2017. Its up 0.12, from 0.98 in 2017Q3. It improved, as 22 investors sold Supernus Pharmaceuticals, Inc. shares while 93 reduced holdings. 43 funds opened positions while 83 raised stakes. 47.19 million shares or 3.19% less from 48.75 million shares in 2017Q3 were reported. Rhumbline Advisers invested 0.01% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Comml Bank Of Mellon Corp reported 1.43M shares stake. Svcs Automobile Association accumulated 0.01% or 86,672 shares. Strs Ohio holds 0.02% or 128,800 shares. Bruce & Inc reported 178,058 shares. New York-based Bamco Ny has invested 0.01% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Axiom Int Invsts Limited De invested in 56,690 shares. Dimensional Fund Advsr Lp owns 1.40M shares for 0.02% of their portfolio. Gotham Asset Management Ltd Liability, a New York-based fund reported 139,597 shares. Ftb stated it has 554 shares or 0% of all its holdings. Granahan Management Inc Ma holds 0.46% of its portfolio in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for 146,396 shares. Capital Finance Advisers Limited Liability Corporation invested in 50,495 shares. 228,556 were reported by Sei Investments Communications. Neumeier Poma Inv Counsel Ltd Liability Corp invested 2.09% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Moreover, Loomis Sayles Limited Partnership has 0.05% invested in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN).

Analysts await Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) to report earnings on August, 1. They expect $0.45 EPS, up 40.63% or $0.13 from last year’s $0.32 per share. SUPN’s profit will be $23.31M for 32.42 P/E if the $0.45 EPS becomes a reality. After $0.49 actual EPS reported by Supernus Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -8.16% negative EPS growth.

Menta Capital Llc decreased Tillys Inc (NYSE:TLYS) stake by 24,960 shares to 27,612 valued at $408,000 in 2017Q4. It also reduced Investors Title Co (NASDAQ:ITIC) stake by 2,578 shares and now owns 1,845 shares. Staar Surgical Co (NASDAQ:STAA) was reduced too.

More recent Builders FirstSource, Inc. (NASDAQ:BLDR) news were published by: Globenewswire.com which released: “Builders FirstSource Reports First Quarter 2018 Results” on May 09, 2018. Also Streetinsider.com published the news titled: “Marcato Capital Shows New Stakes in Astec Industries (ASTE), Univar (UNVR) (more…) – 13f” on May 15, 2018. Streetinsider.com‘s news article titled: “Marcato Capital’s 13F Shows New Stake in Astec Industries (ASTE), Univar (UNVR), Increase in Rayonier (RYAM …” with publication date: May 15, 2018 was also an interesting one.

Investors sentiment decreased to 1 in Q4 2017. Its down 1.02, from 2.02 in 2017Q3. It dived, as 30 investors sold BLDR shares while 79 reduced holdings. 37 funds opened positions while 72 raised stakes. 101.67 million shares or 0.09% less from 101.77 million shares in 2017Q3 were reported. Kennedy Cap Management reported 1.27 million shares stake. Cubist Systematic Strategies Ltd Liability stated it has 6,265 shares or 0.01% of all its holdings. Macquarie Gru Ltd reported 23,700 shares stake. The Massachusetts-based Arrowstreet Cap Lp has invested 0.02% in Builders FirstSource, Inc. (NASDAQ:BLDR). Geode Limited Liability Corporation has invested 0.01% in Builders FirstSource, Inc. (NASDAQ:BLDR). Tci Wealth Advisors has invested 0% in Builders FirstSource, Inc. (NASDAQ:BLDR). Rhumbline Advisers stated it has 0% in Builders FirstSource, Inc. (NASDAQ:BLDR). Hbk Invs Limited Partnership has 0.01% invested in Builders FirstSource, Inc. (NASDAQ:BLDR). Northern Trust owns 1.32M shares. Stelliam Investment Management Limited Partnership stated it has 1.4% in Builders FirstSource, Inc. (NASDAQ:BLDR). James Invest Rech has 337,061 shares for 0.25% of their portfolio. Fisher Asset Management Llc holds 201,769 shares. Wall Street Access Asset Management Limited Liability holds 0.62% or 18,050 shares in its portfolio. Massachusetts-based Congress Asset Management Ma has invested 0.15% in Builders FirstSource, Inc. (NASDAQ:BLDR). Public Employees Retirement Association Of Colorado has invested 0% in Builders FirstSource, Inc. (NASDAQ:BLDR).

Builders FirstSource, Inc. (NASDAQ:BLDR) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>